IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
· cision pr newswire
AI Briefing
- • Ionis Pharmaceuticals sees 20% decline in stock price after Phase-3 trial misses primary endpoint.
- • Market reacts negatively to trial results, with $17 lost in value.
- • SueWallSt notifies investors of potential securities claims involving Ionis Pharmaceuticals.
Source Summary
Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS...
Advertisement